Fexaramine|cas 574013-66-4|DC Chemicals

Cas No.:	574013-66-4
Chemical Name:	Fexaramine
Synonyms:	2-Propenoic acid,3-[3-[(cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-,methyl ester;2-Propenoic acid,3-[3-[(cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]ami...;3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester;Fexaramine;Fexaramine,3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester;3-[3-[(Cyclohexylcarbonyl)[[4′-(dimethylamino)[1,1′-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid methyl ester;(2E)-3-[3-[(Cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid methyl ester;FEX;(E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate;C32H36N2O3;GTPL2744;Fexaramine, >=98% (HPLC);AOB5017;HMS3413H09;HMS3677H09;BCP15784;3671AH;BDBM50167161;DB02545;BC600742;AK175872;B7108;C15649;(E)-3-{3-[Cyclohexanecarbonyl-(4''-di
SMILES:	O=C(C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])N(C1=C([H])C([H])=C([H])C(/C(/[H])=C(\[H])/C(=O)OC([H])([H])[H])=C1[H])C([H])([H])C1C([H])=C([H])C(C2C([H])=C([H])C(=C([H])C=2[H])N(C([H])([H])[H])C([H])([H])[H])=C([H])C=1[H]
Formula:	C₃₂H₃₆N₂O₃
M.Wt:	496.6398
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds. IC50 value:Target:in vitro: In vitro treatment of CDCA or fexaramine elevated the SHP transcript level and occupancy on secretin promoter [1]. Fexaramine significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and β-catenin signaling [2]. By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver [3].

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC71956	BMS-986339	BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues.
DC7040	WAY-362450 (XL335; Turofexorate isopropyl)	WAY-362450 (XL335; Turofexorate isopropyl) is a highly potent, selective, and orally active farnesoid X receptor (FXR) agonist with an EC50 of 4 nM.WAY-362450 is useful for dyslipidemia.
DC10737	Tropifexor (LJN452)	Tropifexor (LJN452) is a highly potent non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
DC10470	SB756050	SB-756050 is a Farnesoid X receptor (FXR) (NR1H4) agonist.
DC7430	Obeticholic acid (INT-747)	INT-747(Obeticholic acid; 6-ECDCA) is a potent and selective FXR agonist(EC50=99 nM) endowed with anticholestatic activity.
DC7566	GW-4064	GW 4064 is a selective, non-steroidal farnesoid X receptor (FXR) agonist (EC50 = 15 nM).
DC8071	Fexarine	Fexarine is a potent, selective farnesoid X receptor agonist.
DC8070	Fexarene	Fexarene is a potent, selective farnesoid X receptor agonist.
DC8085	Fexaramine	Fexaramine is a potent, selective FXR activator.
DC10868	Cilofexor	Cilofexor (GS-9674, GS9674) is novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.